Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a slight decline in stock price and a notable change in financing activities on January 6, with a net financing buy of -2.01 million yuan [1] - On January 6, He Yuan Bio's financing buy amounted to 16.60 million yuan, while the financing repayment was 18.62 million yuan, resulting in a total financing balance of 237 million yuan, which represents 7.99% of its market capitalization [1] - The company specializes in the research, production, and sales of plant-derived human serum albumin using rice endosperm cell recombinant protein expression technology, with its main business revenue composition being 75.44% from recombinant human albumin and 24.56% from other products [1] Group 2 - As of October 28, the number of shareholders of He Yuan Bio reached 47,100, marking an increase of 84,075% compared to the previous period, while the average circulating shares per person decreased by 99.85% to 869 shares [2] - For the period from January to September 2025, He Yuan Bio reported an operating income of 19.66 million yuan, reflecting a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, also down by 8.44% year-on-year [2]
禾元生物1月6日获融资买入1660.23万元，融资余额2.37亿元